Literature DB >> 31267202

Impact of delayed fixation and decalcification on PD-L1 expression: a comparison of two clones.

Fabien Forest1,2, Gaelle Cote3, David Laville3, Vanessa Da Cruz3, Pierre Dal Col3, Florian Camy3, Mousa Mobarki3,4, Alix Clemenson3, Violaine Yvorel3, Michel Péoc'h3,5.   

Abstract

The bone is a frequent localization for lung non-small cell cancer metastasis; decalcification is required to permit tissue section. Pre-analytical conditions can influence the detection of immunohistochemical markers. The aim of our work is to evaluate PD-L1 expression in samples with delayed fixation and in decalcified tissue with chelating agent or acid at different time. Tumor-expressing PD-L1 and placental tissue were fixed at different times or decalcified with an acid decalcifier or EDTA for different durations. For 22C3 antibody, when tissues were decalcified with DC3, there was a significant decrease in the percentage of tumor cells or placental villi stained which after 4 h (p = 0.035 at 4 h). When EDTA is used for 22C3 antibody, there was a slight decrease in the percentage of stained tumor cells or villi but although there was a trend (p = 0.058 at 20 h), this was never statistically significant. For E1L3N antibody, when tissues were decalcified either with DC3 or EDTA, there was no significant decrease for the proportion of stained tumor cells or placental villi, neither for staining intensity for the first 24 h. The proportion of placental villi and tumor stained or intensity of staining was not significantly lower for any sample after delayed fixation also at 24 h for both PD-L1 clones. Delayed fixation does not affect the proportion of stained cell and intensity with PD-L1 immunohistochemistry. Decalcification also performed with EDTA lower the proportion and intensity of stained cells with PD-L1 immunohistochemistry.

Entities:  

Keywords:  Acid decalcifier; Decalcification; Delayed fixation; EDTA; PD-L1

Year:  2019        PMID: 31267202     DOI: 10.1007/s00428-019-02613-w

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  20 in total

1.  EGFR, KRAS, BRAF and HER2 testing in metastatic lung adenocarcinoma: Value of testing on samples with poor specimen adequacy and analysis of discrepancies.

Authors:  Fabien Forest; Marie-Laure Stachowicz; François Casteillo; Georgia Karpathiou; Fabienne Gouzy-Grosjean; Colette Guilaubey; Michèle Cottier; Julie Beal; Alix Clemenson; Michel Péoc'h
Journal:  Exp Mol Pathol       Date:  2017-11-22       Impact factor: 3.362

2.  Effect of delayed formalin fixation on estrogen and progesterone receptors in breast cancer: a study of three different clones.

Authors:  Jingxin Qiu; Swati Kulkarni; Rameela Chandrasekhar; Mark Rees; Kathryn Hyde; Gregory Wilding; Dongfeng Tan; Thaer Khoury
Journal:  Am J Clin Pathol       Date:  2010-11       Impact factor: 2.493

3.  PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.

Authors:  Fred R Hirsch; Abigail McElhinny; Dave Stanforth; James Ranger-Moore; Malinka Jansson; Karina Kulangara; William Richardson; Penny Towne; Debra Hanks; Bharathi Vennapusa; Amita Mistry; Rasika Kalamegham; Steve Averbuch; James Novotny; Eric Rubin; Kenneth Emancipator; Ian McCaffery; J Andrew Williams; Jill Walker; John Longshore; Ming Sound Tsao; Keith M Kerr
Journal:  J Thorac Oncol       Date:  2016-11-29       Impact factor: 15.609

4.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

5.  Influence of decalcification procedures on immunohistochemistry and molecular pathology in breast cancer.

Authors:  Willemijne A M E Schrijver; Petra van der Groep; Laurien Dc Hoefnagel; Natalie D Ter Hoeve; Ton Peeters; Cathy B Moelans; Paul J van Diest
Journal:  Mod Pathol       Date:  2016-08-26       Impact factor: 7.842

6.  The effect of delay in fixation on HER2 expression in invasive carcinoma of the breast assessed with immunohistochemistry and in situ hybridisation.

Authors:  Andrew H S Lee; Heather P Key; Jane A Bell; Patrick Kumah; Zsolt Hodi; Ian O Ellis
Journal:  J Clin Pathol       Date:  2014-04-15       Impact factor: 3.411

Review 7.  Bone metastases from lung cancer: A paradigm for multidisciplinary onco-rheumatology management.

Authors:  Cyrille B Confavreux; Jean-Baptiste Pialat; Aurélie Bellière; Marie Brevet; Chantal Decroisette; Agnès Tescaru; Julien Wegrzyn; Cédric Barrey; Françoise Mornex; Pierre-Jean Souquet; Nicolas Girard
Journal:  Joint Bone Spine       Date:  2018-04-06       Impact factor: 4.929

Review 8.  Delay to Formalin Fixation (Cold Ischemia Time) Effect on Breast Cancer Molecules.

Authors:  Thaer Khoury
Journal:  Am J Clin Pathol       Date:  2018-03-07       Impact factor: 2.493

Review 9.  PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation.

Authors:  Ian A Cree; Richard Booton; Paul Cane; John Gosney; Merdol Ibrahim; Keith Kerr; Rohit Lal; Conrad Lewanski; Neal Navani; Andrew G Nicholson; Marianne Nicolson; Yvonne Summers
Journal:  Histopathology       Date:  2016-06-30       Impact factor: 5.087

10.  Comparable immunoreactivity rates of PD-L1 in archival and recent specimens from non-small cell lung cancer.

Authors:  Yuki Nakamura; Tetsu Kobayashi; Yoichi Nishii; Yuta Suzuki; Haruko Saiki; Kentaro Ito; Fumiaki Watanabe; Kota Nishihama; Taro Yasuma; Corina N D'Alessandro-Gabazza; Koji Katsuta; Hajime Fujimoto; Esteban C Gabazza; Osamu Taguchi; Osamu Hataji
Journal:  Thorac Cancer       Date:  2018-09-12       Impact factor: 3.500

View more
  8 in total

1.  The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC.

Authors:  Mari Mino-Kenudson; Nolwenn Le Stang; Jillian B Daigneault; Andrew G Nicholson; Wendy A Cooper; Anja C Roden; Andre L Moreira; Erik Thunnissen; Mauro Papotti; Giuseppe Pelosi; Noriko Motoi; Claudia Poleri; Elisabeth Brambilla; Mary Redman; Deepali Jain; Sanja Dacic; Yasushi Yatabe; Ming Sound Tsao; Fernando Lopez-Rios; Johan Botling; Gang Chen; Teh-Ying Chou; Fred R Hirsch; Mary Beth Beasley; Alain Borczuk; Lukas Bubendorf; Jin-Haeng Chung; David Hwang; Dongmei Lin; John Longshore; Masayuki Noguchi; Natasha Rekhtman; Lynette Sholl; William Travis; Akihiko Yoshida; Murry W Wynes; Ignacio I Wistuba; Keith M Kerr; Sylvie Lantuejoul
Journal:  J Thorac Oncol       Date:  2021-03-02       Impact factor: 20.121

2.  External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different.

Authors:  Andrew Dodson; Suzanne Parry; Birgit Lissenberg-Witte; Alex Haragan; David Allen; Anthony O'Grady; Emma McClean; Jamie Hughes; Keith Miller; Erik Thunnissen
Journal:  J Pathol Clin Res       Date:  2019-12-17

3.  What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic-Pathologic Correlations.

Authors:  Andrea Palicelli; Martina Bonacini; Stefania Croci; Cristina Magi-Galluzzi; Sofia Cañete-Portillo; Alcides Chaux; Alessandra Bisagni; Eleonora Zanetti; Dario De Biase; Beatrice Melli; Francesca Sanguedolce; Magda Zanelli; Maria Paola Bonasoni; Loredana De Marco; Alessandra Soriano; Stefano Ascani; Maurizio Zizzo; Carolina Castro Ruiz; Antonio De Leo; Guido Giordano; Matteo Landriscina; Giuseppe Carrieri; Luigi Cormio; Daniel M Berney; Jatin Gandhi; Giacomo Santandrea; Maria Carolina Gelli; Alessandro Tafuni; Moira Ragazzi
Journal:  Cells       Date:  2021-11-14       Impact factor: 6.600

4.  Anti-CK7/CK20 Immunohistochemistry Did Not Associate with the Metastatic Site in TTF-1-Negative Lung Cancer.

Authors:  Alice Court; David Laville; Sami Dagher; Vincent Grosjean; Pierre Dal-Col; Violaine Yvorel; François Casteillo; Sophie Bayle-Bleuez; Jean-Michel Vergnon; Fabien Forest
Journal:  Diagnostics (Basel)       Date:  2022-06-29

5.  Programmed Death-Ligand 1 Expression in Lymphovascular Tumor Emboli in Lung Cancer.

Authors:  Yi-Chen Yeh; Hsiu-Hsun Ma; Ping-Yuan Chu; Hsiang-Ling Ho; Teh-Ying Chou
Journal:  JTO Clin Res Rep       Date:  2022-06-08

6.  PD-L1 expression and FGFR-mutations among Danish patients diagnosed with metastatic urothelial carcinoma: A retrospective and descriptive study.

Authors:  Trine Grantzau; Birgitte Grønkaer Toft; Linea Cecilie Melchior; Johanna Elversang; Dag Rune Stormoen; Lise Høj Omland; Helle Pappot
Journal:  APMIS       Date:  2022-06-15       Impact factor: 3.428

Review 7.  PD-L1 Testing in Cytological Non-Small Cell Lung Cancer Specimens: A Comparison with Biopsies and Review of the Literature.

Authors:  Mohammed S I Mansour; Kajsa Ericson Lindquist; Tomas Seidal; Ulrich Mager; Rikard Mohlin; Lena Tran; Kim Hejny; Benjamin Holmgren; Despoina Violidaki; Katalin Dobra; Annika Dejmek; Maria Planck; Hans Brunnström
Journal:  Acta Cytol       Date:  2021-07-07       Impact factor: 2.319

8.  FLINO-A new method for immunofluorescence bioimage normalization.

Authors:  John Graf; Sanghee Cho; Elizabeth McDonough; Alex Corwin; Anup Sood; Andreas Lindner; Manuela Salvucci; Xanthi Stachtea; Sandra Van Schaeybroeck; Philip D Dunne; Pierre Laurent-Puig; Daniel Longley; Jochen H M Prehn; Fiona Ginty
Journal:  Bioinformatics       Date:  2021-10-02       Impact factor: 6.937

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.